NT5C2 K359Q

CI-VAR-00002119Explore in graph →NP_036361.1:p.Lys359GlnNM_012229.4:c.1075A>CClinVar 376350 CIViC 239

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
NT5C2 K359Q	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID667 The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Münster … (full text at CIViC) PMID 23377281 · Tzoneva et al., 2013 · Open in CIViC	civic
T Acute Lymphoblastic Leukemia2
NT5C2 K359Q	Arabinosylguanine + NelarabineSubstitutes	Predictive	D	Does Not Support Resistance	4	accepted	EID636 CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.